Ergoteles’s Myriad Genetics MYGN Stock Holding History

Ergoteles’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-28,710	Closed	-$665K	–	556
2023 Q2	$665K	Buy	28,710 +1,074	+4%	+$23.4K	0.03%	578
2023 Q1	$642K	Buy	27,636 +11,053	+67%	+$224K	0.03%	651
2022 Q4	$241K	Buy	+16,583	New	+$309K	0.01%	995
2022 Q3	–	Sell	-28,637	Closed	-$520K	–	1833
2022 Q2	$520K	Buy	+28,637	New	+$595K	0.02%	820

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Ergoteles's MYGN Position: Q3 2023 in Review

Ergoteles sold out of Myriad Genetics (MYGN) in Q3 2023, closing a stake of 28,710 shares — an estimated $665K sold.

Ergoteles first reported a position in MYGN in Q2 2022 and held it in 4 quarters. The position peaked at $665K in Q2 2023. 186 funds tracked by Wall St. Rank hold MYGN as of Q3 2023.

Ergoteles reported no remaining Myriad Genetics position as of Q3 2023 after selling out during the quarter.
Ergoteles sold 28,710 Myriad Genetics shares in Q3 2023, an estimated $665K.
Ergoteles first reported a position in Myriad Genetics in Q2 2022 and held it in 4 quarters.
Ergoteles's Myriad Genetics position peaked at $665K in Q2 2023.
186 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2023.

Based on Ergoteles's 13F filing for Q3 2023, filed 14 Nov 2023.